Live Breaking News & Updates on Deals andm amp a

Stay informed with the latest breaking news from Deals andm amp a on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Deals andm amp a and stay connected to the pulse of your community

China's investigator trials accelerate competitive CAR T development

China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.

China , Nanjing , Jiangsu , Chinese , Wuxi-apptec-co , Juventas-cell-therapy-ltd , Pharmaceuticals-inc , Juno-therapeutics-inc , Legend-biotech-corp , Johnson , Nanjing-legend-biotech-corp

Bruker unties Nanostring bankruptcy knot with $393M winning bid

Bruker Corp. shows no sign of slowing its buying binge, picking up Nanostring Technologies Inc. for $392.6 million in cash plus the assumption of certain liabilities in its seventh deal so far this year.
Nanostring entered bankruptcy in February and received a “stalking horse” bid of $220 million from private equity fund Patient Square Capital in March. Bruker won the competitive auction for Nanostring’s assets, besting the Patient Square bid by 78%. The deal is expected to close in early May.

Bruker-corp , Nanostring-technologies-inc , Nanostring-technologies , Patient-square-capital , Patient-square , Bioworld-medtech , Bruker-corp- , Nanostring-technologies-inc- , Geomx , Cosmx , Elistechgroup-sas

Vertex buying Alpine for $4.9B for phase III-ready IgAN asset

Vertex Pharmaceuticals Inc. is acquiring Alpine Immune Sciences Inc. for $4.9 billion in cash to gain Alpine’s lead product, phase III-ready povetacicept, which demonstrates best-in-class potential in patients with immunoglobulin A nephropathy (IgAN).

Reshma-kewalramani , Vertex-pharmaceuticals-inc , Alpine-immune-sciences-inc , Vertex-pharmaceuticals , Alpine-immune-sciences , Alpine-immune-sciences-inc- , Vertex-pharmaceuticals-inc- , Kidney-disease , Igan , Immunoglobulina-nephropathy , Immunoglobulin-a , Povetacicept

J&J paces interventional cardio market with $13B Shockwave buy

Med-tech powerhouse Johnson & Johnson made a bold bid to bolster its interventional cardiology holdings with the news on April 5 that it is acquiring Shockwave Medical Inc. for approximately $13.1 billion including cash acquired. The $335 per share cash price represents a more than 5% premium to Shockwave’s (Nasdaq: SWAV) April 4 closing price and a more than 17% premium to the stock price prior to the Wall Street Journal report last week about the rumoured deal.

Shockwave-medical-inc , Johnson , Shockwave-medical , Wall-street-journal , Deals-andm-amp-a , Bioworld-medtech , Cardiovascular , Johnson-amp , Shockwave-medical-inc- , Coronary-artery-disease , Peripheral-artery-disease

Asensus weighs $96M Storz offer, takes $20M bridge loan

Asensus Surgical Inc. grabbed a $10 million lifeline from prospective suitor Karl Storz SE & Co. KG, which has offered to buy the cash-strapped company for 35 cents per share or about $96 million. Asensus signed a non-binding letter of intent to consider and negotiate terms after “an extensive period of consideration of various strategic alternatives.” Under certain circumstances, it could access a further $10 million from Storz prior to a merger. Asensus reported in March that its cash runway would tap out in early July.

Karl-storz-se-co , Asensus-surgical-inc , Asensus-surgical , Karl-storz , Bioworld-medtech , Asensus-surgical-inc- , Karl-storz-se-amp-co-kg , Transenterix-inc- , Senhance , Levita-magnetics-international-corp- , Cmr-surgical-ltd-

In first major M&A, Genmab adding Profoundbio for $1.8B

Investors might not have been overly excited, but Genmab A/S executives enthused about the “complementarity” of its proposed acquisition of antibody-drug conjugate (ADC) specialist Profoundbio Inc. for $1.8 billion in cash. The deal, expected to close in the first half of 2024, marks the biggest by far for the Copenhagen, Denmark-based biopharma and the latest transaction for the red hot ADC space.

Denmark , Copenhagen , Køavn- , Profoundbio-inc , Genmaba-s , Profoundbio-inc- , Adc , Bioworld , Deals-andm-amp-a , Antibody-drug-conjugate , Cancer

Novo nabs Cardior in €1B deal, gaining phase II-stage miRNA drug

In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.

Claudia-ulbrich , Novo-nordisk , Cardior-pharmaceuticals-gmb , Pharmaceuticals-gmbh , Novo-nordiska-s , Cardior-pharmaceuticals-gmbh , Cdr-132l , Heart-disease , Mir-132 , Mirna , Bioworld

Sound decision: Masimo to split off consumer business

Less than two years after acquiring Sound United for $1.025 billion, Masimo Corp. plans to hive off the consumer audio subsidiary along with consumer health products such as its Stork baby monitor and Freedom smart watch and band. The “rushed” announcement made Friday “came after being informed that Politan intended to nominate directors this week,” said activist investor Politan Capital Management. Politan, which owns 8.9% of the company, secured two board seats in a highly contentious proxy battle last year and nominated two more on Monday morning.

Masimo-corp , Sound-united , Politan-capital , Bioworld-medtech , Masimo-corp- , Spin-off , Sound-united-llc , Apple-inc- , Diagnostics , Us- , Deals-andm-amp-a

Nuvation to buy Anheart, cancer pipeline in all-stock deal

Nuvation Bio Inc. said on March 25 it will acquire Anheart Therapeutics Ltd., a U.S.- and China-based precision oncology company, in an all-stock transaction, adding Anheart’s ROS1-inhibiting lung cancer drug, taletrectinib (AB-106), to its pipeline.

China , Nuvation-bio-inc , Anheart-therapeutics-ltd , Nuvation-bio , Nuvation-bio-inc- , Anheart-therapeutics-ltd- , Ros1-inhibitor , Lung-cancer , Non-small-cell-lung-cancer , Nsclc , Taletrectinib

Recoded organisms pioneer Pearl Bio signs $1B Merck deal

Technology of genomically recoded organisms borne out of Yale and Stanford university laboratories and housed at Khosla Ventures-backed Pearl Bio received validation on March 12 through a $1 billion deal signed with Merck & Co. Inc. Cambridge, Mass.-based Pearl, which emerged from stealth last year, is eligible for the funds through up-front, option and milestone payments, plus potential royalties on sales of deal-related products that gain approval.

Stanford , Leicestershire , United-kingdom , Cambridge , Cambridgeshire , Pearl-bio , Merck-co , Khosla-ventures-backed-pearl-bio , Merck-amp-co-inc- , Recoded-organisms , Bioworld , Deals-andm-amp-a